Jacek Gan Selected Research

lorukafusp alfa

10/2019	Antitumor Activity and Tolerability of hu14.18-IL2 with GMCSF and Isotretinoin in Recurrent or Refractory Neuroblastoma: A Children's Oncology Group Phase II Study.
10/2018	Pilot trial of the hu14.18-IL2 immunocytokine in patients with completely resectable recurrent stage III or stage IV melanoma.
8/2013	Intratumoral treatment of smaller mouse neuroblastoma tumors with a recombinant protein consisting of IL-2 linked to the hu14.18 antibody increases intratumoral CD8+ T and NK cells and improves survival.
12/2012	Phase II trial of hu14.18-IL2 for patients with metastatic melanoma.
4/2011	Differential internalization of hu14.18-IL2 immunocytokine by NK and tumor cell: impact on conjugation, cytotoxicity, and targeting.
12/2010	Genotypes of NK cell KIR receptors, their ligands, and Fcγ receptors in the response of neuroblastoma patients to Hu14.18-IL2 immunotherapy.
11/2010	Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II study.
9/2009	Immunogenicity of the hu14.18-IL2 immunocytokine molecule in adults with melanoma and children with neuroblastoma.
3/2006	A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group.
11/2004	Phase I clinical trial of the immunocytokine EMD 273063 in melanoma patients.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jacek Gan Research Topics

Disease

10	Neuroblastoma 01/2021 - 03/2006
7	Neoplasms (Cancer) 01/2020 - 06/2003
7	Melanoma (Melanoma, Malignant) 10/2018 - 11/2004
5	Hypotension (Low Blood Pressure) 12/2012 - 11/2004
3	Lymphocytosis 12/2012 - 11/2004
3	Hypersensitivity (Allergy) 11/2010 - 07/2006
3	Pain (Aches) 11/2010 - 07/2006
2	Residual Neoplasm 10/2019 - 12/2012
2	Hyperbilirubinemia 11/2010 - 11/2004
2	Hypoxia (Hypoxemia) 11/2010 - 11/2004
1	Disease Progression 01/2020
1	Hematologic Neoplasms (Hematological Malignancy) 01/2016
1	Acute Erythroblastic Leukemia (Erythroleukemia) 01/2016
1	Renal Insufficiency (Renal Failure) 12/2012
1	Oliguria 12/2012
1	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 09/2011
1	Exanthema (Rash) 11/2010
1	Diarrhea 01/2009
1	Fever (Fevers) 01/2009
1	Nausea 01/2009
1	Urticaria (Hives) 01/2009
1	Vomiting 01/2009
1	Capillary Leak Syndrome 01/2009
1	Sarcoma (Soft Tissue Sarcoma) 07/2006
1	Arthralgia (Joint Pain) 11/2004
1	Hypophosphatemia 11/2004
1	Thrombocytopenia (Thrombopenia) 11/2004
1	Hyperglycemia 11/2004
1	Ovarian Neoplasms (Ovarian Cancer) 05/2004
1	Ascites 05/2004
1	Ovarian Epithelial Carcinoma 05/2004

Drug/Important Bio-Agent (IBA)

10	lorukafusp alfaIBA 10/2019 - 11/2004
9	Interleukin-2 (IL2)IBA 01/2021 - 03/2006
6	Monoclonal AntibodiesIBA 01/2020 - 06/2003
5	dinutuximabIBA 01/2021 - 07/2006
4	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 01/2021 - 01/2007
4	CytokinesIBA 01/2021 - 06/2003
3	Interleukin-2 Receptors (IL 2 Receptor)IBA 09/2011 - 11/2004
3	Transaminases (Aminotransferases)IBA 11/2010 - 11/2004
2	Immunoglobulins (Immunoglobulin)IBA 01/2020 - 01/2016
2	AntibodiesIBA 01/2020 - 07/2006
2	LigandsIBA 01/2016 - 12/2010
2	KIR ReceptorsIBA 01/2016 - 12/2010
2	Proteins (Proteins, Gene)FDA Link 11/2010 - 06/2003
2	Dopamine (Intropin)FDA LinkGeneric 11/2010 - 03/2006
1	Panitumumab (Vectibix)FDA Link 01/2020
1	Immunoglobulin G (IgG)IBA 01/2020
1	Isotretinoin (Accutane)FDA LinkGeneric 10/2019
1	Interleukin-15 (Interleukin 15)IBA 01/2016
1	Recombinant ProteinsIBA 08/2013
1	C-Reactive ProteinIBA 12/2012
1	Peptides (Polypeptides)IBA 01/2007
1	chironIBA 07/2006
1	Opioid Analgesics (Opioids)IBA 11/2004
1	Epithelial Cell Adhesion MoleculeIBA 05/2004
1	ChromiumIBA 05/2004
1	tucotuzumab celmoleukinIBA 05/2004
1	Therapeutic UsesIBA 05/2004

Therapy/Procedure

9	Therapeutics 01/2021 - 05/2004
5	Immunotherapy 01/2021 - 05/2004
1	Intravenous Infusions 12/2012
1	Drug Tapering 12/2012
1	Bone Marrow Transplantation (Transplantation, Bone Marrow) 01/2009
1	Cytoreduction Surgical Procedures 05/2004